Skip to main content
Rafael Holdings, Inc. logo

Rafael Holdings, Inc. — Investor Relations & Filings

Ticker · RFL ISIN · US75062C1009 US Professional, scientific and technical activities
Open in API
Filings indexed 393 across all filing types
Latest filing 2024-06-19 Major Shareholding Noti…
Country US United States of America
Listing US RFL

About Rafael Holdings, Inc.

https://rafaelholdings.com

Rafael Holdings, Inc. is a clinical-stage biotechnology company that invests in and develops therapies for difficult-to-treat diseases. The company holds interests in early-stage and clinical pharmaceutical entities, with a primary focus on novel cancer therapeutics aimed at improving and extending the lives of patients. Following a merger with Cyclo Therapeutics, Rafael Holdings is also advancing a potential breakthrough treatment for Niemann-Pick Type C1, a rare genetic disorder.

Recent filings

Filing Released Lang Actions
AMENDMENT NO. 3 TO SCHEDULE 13D
Major Shareholding Notification
2024-06-19 English
4
Director's Dealing
2024-06-17 English
QUARTERLY REPORT
Interim / Quarterly Report Q3 2024
2024-06-14 English
CURRENT REPORT
Earnings Release Classification · 100% confidence The document is a Form 8-K filed with the SEC by Rafael Holdings, Inc. dated June 14, 2024. It specifically references Item 2.02 "Results of Operations and Financial Condition" and includes a press release reporting the results of operations for the fiscal quarter ended April 30, 2024. The document states that the earnings release is furnished as Exhibit 99.1 and is incorporated by reference. The content is typical of an earnings release announcement filed on Form 8-K, which is used to report quarterly financial results outside of the full quarterly report (10-Q). The document does not contain the full financial statements or detailed analysis but rather announces the earnings release. Therefore, the appropriate classification is Earnings Release (ER). The document length is just over 5,000 characters, but the content and form type clearly indicate an earnings release announcement rather than a full interim report or annual report.
2024-06-14 English
AMENDMENT NO. 1 TO FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K/A, which is an amendment to a previously filed Form 8-K. It is filed pursuant to the Securities Exchange Act of 1934 and includes financial statements and pro forma financial information related to an acquisition and restructuring. The document contains audited and unaudited financial statements of an acquired business and pro forma combined financial statements. The presence of these financial statements and pro forma information in an 8-K amendment indicates it is a regulatory filing updating prior disclosures rather than a full annual or quarterly report. The document is not a full Annual Report (10-K) or Interim Report (IR), nor is it a simple announcement or certification. It is a Current Report amendment with financial exhibits, which fits best under Regulatory Filings (RNS) as it does not match other more specific categories like Earnings Release or M&A Activity filings. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2024-05-23 English
4
Director's Dealing
2024-04-08 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.